 |
 |
Maryse, I perused the Comtan web site and now understand your earlier question. Although it is advertised as a COMT inhibitor their claim is that efficacy is due to extending plasma levels of levadopa making more available to cross the brain blood barrier. No claims are made about it's action in the brain. One would therefore not think that Comtan would be a suitable monotherapy without levadopa. So I stand corrected. Phil Gesotti 51/dx46 ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn